Amarin CORP Plc\uk: management transactions · United States · SEC (Form 4)

About Amarin CORP Plc\uk

Amarin Corporation plc (ticker: AMRN) is a U.S.-listed biopharmaceutical company trading on the NASDAQ in the United States. For French-speaking investors, Amarin is best understood as a cardiovascular-focused pharmaceutical specialist whose investment case is centered on a single flagship asset: VASCEPA® in the U.S. and VAZKEPA® internationally, both based on icosapent ethyl. The company’s stated mission is to advance cardiovascular care and reduce risk in high-risk patient populations, which makes it a highly focused healthcare name rather than a broad diversified pharma platform. ([amarincorp.com](https://www.amarincorp.com/news-and-media/amarin-reports-2026-first-quarter-financial-results?utm_source=openai)) From a historical perspective, Amarin built its identity in cardiovascular research and development, with an R&D headquarters in Mystic, Connecticut. The company now communicates operationally from Dublin, Ireland and Bridgewater, New Jersey, reflecting an international corporate setup with U.S. commercial roots and global execution capabilities. Over time, Amarin has shifted from a more development-centric profile toward a commercialization-led model focused on maximizing the global value of VASCEPA/VAZKEPA. ([amarincorp.com](https://www.amarincorp.com/about-amarin?utm_source=openai)) Amarin’s core business is the commercialization of icosapent ethyl, a differentiated prescription therapy positioned in cardiovascular risk reduction. In the U.S., management emphasizes the resilience of the franchise even after generic competition entered the market. Internationally, the company has increasingly relied on licensing and supply partnerships to expand access without carrying the full burden of country-by-country commercial infrastructure. Competitive pressure comes from generic icosapent ethyl products as well as broader lipid-management and cardiovascular-risk therapies, so the company’s moat depends heavily on clinical differentiation, reimbursement access, and execution. ([amarincorp.com](https://www.amarincorp.com/news-and-media/amarin-reports-2026-first-quarter-financial-results?utm_source=openai)) Geographically, Amarin remains anchored in the United States while pursuing a more partner-driven international footprint across multiple countries. Recent company commentary indicates a fully partnered global model covering a broad network of markets, which supports a more capital-efficient approach to expansion. For market context, AMRN is listed on NASDAQ in the United States, an important detail for investors following SEC Form 4 insider transaction filings and other U.S. disclosure documents. ([investors.amarincorp.com](https://investors.amarincorp.com/news-releases/news-release-details/amarin-reports-third-quarter-2025-financial-results?utm_source=openai)) Recent milestones are notable. In 2025, Amarin announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe, highlighted additional REDUCE-IT scientific analyses, and in early 2026 reported improved operating momentum, including cash flow turning positive earlier than previously expected. The company also said it regained compliance with Nasdaq’s minimum bid-price requirement in April 2025, which is relevant from a risk-management and listing-stability standpoint. Overall, Amarin remains a specialized cardiovascular pharma story driven by the commercial durability of its lead product and the monetization of its international franchise. ([investors.amarincorp.com](https://investors.amarincorp.com/news-releases/news-release-details/amarin-announces-exclusive-license-and-supply-agreement?utm_source=openai))